Orion raises outlook after Merck deal on developing prostate cancer drug

Finnish drug maker Orion (ORNBV.HE) on Wednesday raised its full year outlook after it signed a collaboration agreement with Merck aimed at developing a prostate cancer drug, sending its shares to two-year high.